Abl Bio Stock Current Asset
| 298380 Stock | KRW 26,600 1,250 4.49% |
ABL Bio fundamentals help investors to digest information that contributes to ABL Bio's financial success or failures. It also enables traders to predict the movement of ABL Stock. The fundamental analysis module provides a way to measure ABL Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABL Bio stock.
ABL |
ABL Bio Company Current Asset Analysis
ABL Bio's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, ABL Bio has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all Republic of Korea stocks is 100.0% higher than that of the company.
Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
ABL Fundamentals
| Return On Equity | 5.6 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 866.33 B | |||
| Shares Outstanding | 45.3 M | |||
| Shares Owned By Insiders | 31.53 % | |||
| Shares Owned By Institutions | 12.89 % | |||
| Price To Sales | 101.38 X | |||
| Revenue | 5.33 B | |||
| Gross Profit | 8.06 B | |||
| EBITDA | (53.58 B) | |||
| Net Income | (43.56 B) | |||
| Cash And Equivalents | 21.59 B | |||
| Total Debt | 72.32 M | |||
| Debt To Equity | 1.40 % | |||
| Current Ratio | 14.71 X | |||
| Cash Flow From Operations | (40.61 B) | |||
| Beta | 1.08 | |||
| Market Capitalization | 958.17 B | |||
| Total Asset | 65.45 B | |||
| Net Asset | 65.45 B |
About ABL Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABL Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABL Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABL Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ABL Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABL Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABL Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with ABL Stock
Moving against ABL Stock
The ability to find closely correlated positions to ABL Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABL Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABL Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABL Bio to buy it.
The correlation of ABL Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABL Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABL Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABL Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in ABL Stock
ABL Bio financial ratios help investors to determine whether ABL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABL with respect to the benefits of owning ABL Bio security.